Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-Q Quarterly Report HTML 626K
11: EX-102 Asset Data HTML 31K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
4: EX-32 Certification -- §906 - SOA'02 HTML 30K
12: R1 Document and Entity Information HTML 47K
13: R2 Consolidated Balance Sheets (Unaudited) HTML 137K
14: R3 Consolidated Balance Sheets (Unaudited) HTML 48K
(Parenthetical)
15: R4 Consolidated Statements of Operations (Unaudited) HTML 101K
16: R5 Consolidated Statements of Comprehensive (Loss) HTML 49K
(Unaudited)
17: R6 Consolidated Statements of Comprehensive (Loss) HTML 33K
(Unaudited) (Parenthetical)
18: R7 Consolidated Statements of Cash Flows (Unaudited) HTML 124K
19: R8 Basis of Presentation HTML 59K
20: R9 Summary of Significant Accounting Policies HTML 46K
21: R10 Marketable Securities HTML 73K
22: R11 Acquisitions HTML 100K
23: R12 Goodwill and Intangible Assets HTML 94K
24: R13 Equity Method Investments HTML 46K
25: R14 Line of Credit HTML 32K
26: R15 Income Taxes HTML 36K
27: R16 Other Balance Sheet Information HTML 82K
28: R17 Derivative Instruments HTML 128K
29: R18 Stock-Based Compensation HTML 79K
30: R19 Earnings per Share HTML 57K
31: R20 Restructuring and Other Charges HTML 96K
32: R21 Employee Benefit Plans HTML 50K
33: R22 Segment Information HTML 144K
34: R23 Significant Customers HTML 34K
35: R24 Fair Value Measurements HTML 139K
36: R25 Commitments and Contingencies HTML 38K
37: R26 Subsequent Events HTML 30K
38: R27 Summary of Significant Accounting Policies HTML 50K
(Policies)
39: R28 Basis of Presentation (Tables) HTML 55K
40: R29 Marketable Securities (Tables) HTML 67K
41: R30 Acquisitions (Tables) HTML 65K
42: R31 Goodwill and Intangible Assets (Tables) HTML 92K
43: R32 Other Balance Sheet Information (Tables) HTML 80K
44: R33 Derivative Instruments (Tables) HTML 119K
45: R34 Stock-Based Compensation (Tables) HTML 63K
46: R35 Earnings per Share (Tables) HTML 55K
47: R36 Restructuring and Other Charges (Tables) HTML 76K
48: R37 Employee Benefit Plans (Tables) HTML 48K
49: R38 Segment Information (Tables) HTML 143K
50: R39 Fair Value Measurements (Tables) HTML 116K
51: R40 Basis of Presentation Summary of the Error HTML 40K
Corrections and Prior Period Adjustments (Details)
52: R41 Summary of Significant Accounting Policies HTML 30K
(Details)
53: R42 Marketable Securities Narrative (Details) HTML 44K
54: R43 Marketable Securities Summary of Marketable HTML 47K
Securities Including Accrued Interest Receivable
(Detail)
55: R44 Marketable Securities Fair Value of Marketable HTML 39K
Securities by Contractual Maturity (Detail)
56: R45 Acquisitions - Narrative (Detail) HTML 153K
57: R46 Acquisitions - Amounts of Assets and Liabilities HTML 71K
at Fair Value as of Acquisition Date (Detail)
58: R47 Acquisitions - Pro Forma Information (Details) HTML 41K
59: R48 Goodwill and Intangible Assets Components of HTML 47K
Goodwill by Business Segment (Detail)
60: R49 Goodwill and Intangible Assets Components of HTML 45K
Identifiable Intangible Assets (Detail)
61: R50 Goodwill and Intangible Assets Narrative (Details) HTML 35K
62: R51 Goodwill and Intangible Assets Estimated Future HTML 43K
Amortization Expense of Intangible Assets
(Details)
63: R52 Equity Method Investments BioCision, LLC (Detail) HTML 120K
64: R53 Equity Method Investments ULVAC Cryogenics, Inc. HTML 48K
(Detail)
65: R54 Line of Credit (Details) HTML 41K
66: R55 Income Taxes Narrative (Detail) HTML 35K
67: R56 Other Balance Sheet Information - Summary of HTML 39K
Account Receivable (Detail)
68: R57 Other Balance Sheet Information - Summary of HTML 36K
Inventories (Detail)
69: R58 Other Balance Sheet Information - Narrative HTML 60K
(Details)
70: R59 Other Balance Sheet Information - Product Warranty HTML 35K
and Retrofit Activity on Gross Basis (Detail)
71: R60 Derivative Instruments - Realized Gains (Losses) HTML 29K
on Derivative Instruments (Details)
72: R61 Derivative Instruments - Notional Amounts HTML 83K
Outstanding under Foreign Currency Contracts
(Detail)
73: R62 Derivative Instruments - Stock Warrant (Details) HTML 32K
74: R63 Stock-Based Compensation - Stock-Based HTML 34K
Compensation Expense (Detail)
75: R64 Stock-Based Compensation - Status of Restricted HTML 62K
Stock Activity and Changes (Detail)
76: R65 Stock-Based Compensation - Narrative (Detail) HTML 97K
77: R66 Earnings per Share Reconciliation of Weighted HTML 48K
Average Common Shares Outstanding for Purposes of
Calculating Basic and Diluted Earnings Per Share
(Detail)
78: R67 Earnings per Share Narrative (Detail) HTML 33K
79: R68 Restructuring and Other Charges Narrative (Detail) HTML 91K
80: R69 Restructuring and Other Charges Activity Related HTML 43K
to Restructuring Accruals (Detail)
81: R70 Employee Benefit Plans Narrative (Detail) HTML 28K
82: R71 Employee Benefit Plans Components of Net Pension HTML 41K
Cost (Detail)
83: R72 Segment Information - Narrative (Detail) HTML 31K
84: R73 Segment Information - Financial Information for HTML 58K
Business Segments (Detail)
85: R74 Segment Information - Reconciliation of Reportable HTML 40K
Segment Operating Income (Loss) to Corresponding
Consolidated Amounts (Detail)
86: R75 Segment Information - Reconciliation of Reportable HTML 39K
Segment Assets to Corresponding Consolidated
Amounts (Detail)
87: R76 Significant Customers Narrative (Detail) HTML 35K
88: R77 Fair Value Measurements - Assets and Liabilities HTML 73K
Measured at Fair Value on Recurring Basis (Detail)
89: R78 Fair Value Measurements - Narrative (Detail) HTML 130K
90: R79 Fair Value Measurements - Reconciliation of Assets HTML 58K
and Liabilities Measured Using Significant
Unobservable Inputs (Details)
91: R80 Commitments and Contingencies - Operating Leases HTML 36K
(Details)
92: R81 Commitments and Contingencies - Letters of Credit HTML 28K
(Details)
93: R82 Commitments and Contingencies - Contingencies HTML 35K
(Details)
94: R83 Subsequent Events (Detail) HTML 36K
96: XML IDEA XML File -- Filing Summary XML 177K
95: EXCEL IDEA Workbook of Financial Reports XLSX 107K
5: EX-101.INS XBRL Instance -- brks-20170331 XML 2.92M
7: EX-101.CAL XBRL Calculations -- brks-20170331_cal XML 256K
8: EX-101.DEF XBRL Definitions -- brks-20170331_def XML 840K
9: EX-101.LAB XBRL Labels -- brks-20170331_lab XML 1.84M
10: EX-101.PRE XBRL Presentations -- brks-20170331_pre XML 1.17M
6: EX-101.SCH XBRL Schema -- brks-20170331 XSD 187K
97: ZIP XBRL Zipped Folder -- 0000933974-17-000015-xbrl Zip 283K
In
light of your continued performance in the senior executive role as Senior Vice President and General Manager, Brooks Semiconductor Solutions Group, Brooks has agreed to provide you with eligibility for salary continuation in the event there is a termination of your employment as set forth below in this letter.
1.
If Brooks terminates your employment without “cause” (as defined in Brooks’ equity grant documents), or you terminate your employment for “good reason” (as defined below), you will be eligible for salary continuation payments at your then current base salary for a period of six (6) months from your termination date. If you have not secured employment following the initial six (6) months of salary continuation, Brooks will continue your salary
on a bi-weekly basis for up to six (6) additional months while you are not employed. In addition, you will continue to be covered under the Company’s medical, dental and vision plans at the same contribution level as current active employees. In exchange, you agree to sign the Company’s customary Separation Agreement and Waiver of Claims. For the sake of clarity, the salary continuation benefits described above shall not apply to any termination of employment that triggers a payment to you under the Change in Control Agreement dated as of November 8, 2016 between you and the Company.
2.
For
purposes hereof, “good reason” shall mean, without your express written consent, the occurrence of any of the following: (i) a material breach by the Company of any agreement that exists between you and the Company; (ii) a diminution of your responsibilities and authority resulting in responsibilities and authority in material respects inconsistent with the responsibilities and authority of the role of Senior Vice President and General Manager, Brooks Semiconductor Solutions Group of the Company; (iii) a reduction of your base salary or of any material employee benefit enjoyed by you unless all senior executives of the Company
suffer a substantially similar reduction; or (iv) a relocation of your office to a location more than 60 miles from the Company’s headquarters in Chelmsford, Massachusetts.”
Please acknowledge your agreement with the terms of this letter by signing and returning a copy hereof.
